28.08.2008, 18:21
Pharmstandard Released Presentation of 1H 2008 Results
OREANDA-NEWS. On 28 August 2008 was , that Pharmstandard announced its 1H 2008 achievements
• Leading domestic pharmaceutical company in Russia (measured by sales)
• #2 pharma company overall in Russia by sales value in 1H 2008
• #1 pharma company in the commercial segment by sales value in 1H 2008
• Industry leading growth and profitability
• Revenue growth of 40% to RUR 6,198 mln (US\\$259 mln) in 1H 2008
• EBITDA growth +62% and to RUR 2,621 mln (US\\$110 mln) in 1H 2008, EBITDA margin equals 42%
• Net profit grew by 83% to RUR 1,757 mln (US\\$ 73 mln)
• Market leading brands and new products
• 7 brands among top-15 best selling domestic brands in Russia
• Launched 8 new products
• Experienced sales force and modern and efficient manufacturing facilities
• More than 445 sales force (hired more than 100 people)
• Launched new workshop for capsules in Kursk
• RUR 381 mln (US\\$ 16 mln) invested in modernisation of production facilities
• Consolidated interest in Ufa, Kursk and Tyumen subsidiaries up to 99%, 97%, and 96% of shares
• Leading domestic pharmaceutical company in Russia (measured by sales)
• #2 pharma company overall in Russia by sales value in 1H 2008
• #1 pharma company in the commercial segment by sales value in 1H 2008
• Industry leading growth and profitability
• Revenue growth of 40% to RUR 6,198 mln (US\\$259 mln) in 1H 2008
• EBITDA growth +62% and to RUR 2,621 mln (US\\$110 mln) in 1H 2008, EBITDA margin equals 42%
• Net profit grew by 83% to RUR 1,757 mln (US\\$ 73 mln)
• Market leading brands and new products
• 7 brands among top-15 best selling domestic brands in Russia
• Launched 8 new products
• Experienced sales force and modern and efficient manufacturing facilities
• More than 445 sales force (hired more than 100 people)
• Launched new workshop for capsules in Kursk
• RUR 381 mln (US\\$ 16 mln) invested in modernisation of production facilities
• Consolidated interest in Ufa, Kursk and Tyumen subsidiaries up to 99%, 97%, and 96% of shares
Комментарии